Jaspreet Singh Sandhu, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Incontinence | 22 | 2023 | 496 | 5.660 |
Why?
|
| Prostatectomy | 36 | 2023 | 1890 | 4.980 |
Why?
|
| Urinary Sphincter, Artificial | 11 | 2018 | 24 | 3.920 |
Why?
|
| Urethra | 14 | 2023 | 408 | 3.260 |
Why?
|
| Prostatic Hyperplasia | 9 | 2023 | 523 | 2.730 |
Why?
|
| Transurethral Resection of Prostate | 5 | 2023 | 83 | 2.610 |
Why?
|
| Urinary Bladder, Overactive | 5 | 2021 | 106 | 2.420 |
Why?
|
| Urology | 8 | 2021 | 399 | 2.300 |
Why?
|
| Urinary Incontinence, Stress | 8 | 2019 | 183 | 2.210 |
Why?
|
| Laser Therapy | 7 | 2023 | 1072 | 2.080 |
Why?
|
| Cystectomy | 9 | 2021 | 686 | 2.030 |
Why?
|
| Urinary Diversion | 5 | 2021 | 138 | 2.020 |
Why?
|
| Prostatic Neoplasms | 30 | 2023 | 11124 | 1.920 |
Why?
|
| Ureter | 4 | 2021 | 375 | 1.870 |
Why?
|
| Urologic Surgical Procedures, Male | 7 | 2019 | 75 | 1.690 |
Why?
|
| Urethral Stricture | 4 | 2014 | 51 | 1.460 |
Why?
|
| Urinary Bladder Neoplasms | 9 | 2021 | 2245 | 1.460 |
Why?
|
| Urodynamics | 9 | 2017 | 347 | 1.340 |
Why?
|
| Pelvic Neoplasms | 2 | 2021 | 254 | 1.340 |
Why?
|
| Urinary Bladder | 5 | 2021 | 1172 | 1.180 |
Why?
|
| Urologic Surgical Procedures | 6 | 2018 | 302 | 1.110 |
Why?
|
| Postoperative Complications | 16 | 2021 | 15295 | 1.090 |
Why?
|
| Prostatitis | 3 | 2011 | 102 | 1.040 |
Why?
|
| Urination Disorders | 3 | 2018 | 241 | 1.010 |
Why?
|
| Erectile Dysfunction | 8 | 2021 | 461 | 0.980 |
Why?
|
| Recovery of Function | 8 | 2023 | 2925 | 0.870 |
Why?
|
| Nocturia | 1 | 2021 | 19 | 0.820 |
Why?
|
| Cystostomy | 1 | 2021 | 26 | 0.810 |
Why?
|
| Suburethral Slings | 3 | 2019 | 76 | 0.780 |
Why?
|
| Pelvic Floor | 3 | 2012 | 138 | 0.770 |
Why?
|
| Replantation | 1 | 2021 | 148 | 0.740 |
Why?
|
| Certification | 3 | 2012 | 424 | 0.740 |
Why?
|
| Prostatism | 1 | 2019 | 14 | 0.710 |
Why?
|
| Ileum | 2 | 2020 | 565 | 0.690 |
Why?
|
| Prostate-Specific Antigen | 6 | 2012 | 2494 | 0.680 |
Why?
|
| Prostatic Diseases | 1 | 2019 | 56 | 0.680 |
Why?
|
| Surgically-Created Structures | 1 | 2018 | 10 | 0.650 |
Why?
|
| Penile Erection | 2 | 2015 | 97 | 0.650 |
Why?
|
| Implantable Neurostimulators | 1 | 2018 | 77 | 0.610 |
Why?
|
| Hypogonadism | 1 | 2023 | 799 | 0.580 |
Why?
|
| Pelvis | 2 | 2018 | 730 | 0.570 |
Why?
|
| Dissection | 1 | 2018 | 295 | 0.570 |
Why?
|
| Hematoma | 1 | 2021 | 758 | 0.570 |
Why?
|
| Watchful Waiting | 1 | 2021 | 492 | 0.560 |
Why?
|
| Sacrum | 1 | 2018 | 288 | 0.550 |
Why?
|
| Connective Tissue | 1 | 2018 | 420 | 0.550 |
Why?
|
| Electric Stimulation Therapy | 2 | 2018 | 605 | 0.510 |
Why?
|
| Male | 77 | 2023 | 350118 | 0.500 |
Why?
|
| Nomograms | 2 | 2015 | 228 | 0.470 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 642 | 0.450 |
Why?
|
| Urinary Bladder Fistula | 1 | 2012 | 9 | 0.440 |
Why?
|
| Directive Counseling | 1 | 2014 | 166 | 0.430 |
Why?
|
| Pelvic Exenteration | 2 | 2022 | 22 | 0.420 |
Why?
|
| Penile Implantation | 2 | 2021 | 16 | 0.410 |
Why?
|
| Cholesterol, HDL | 1 | 2018 | 1814 | 0.410 |
Why?
|
| Penile Prosthesis | 2 | 2021 | 38 | 0.400 |
Why?
|
| Private Practice | 1 | 2012 | 154 | 0.400 |
Why?
|
| Pelvic Organ Prolapse | 1 | 2013 | 135 | 0.400 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2011 | 81 | 0.380 |
Why?
|
| Humans | 89 | 2023 | 744343 | 0.370 |
Why?
|
| Cystoscopy | 3 | 2015 | 134 | 0.360 |
Why?
|
| Urinary Catheterization | 1 | 2011 | 202 | 0.350 |
Why?
|
| Professional Practice | 1 | 2012 | 326 | 0.350 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 3610 | 0.350 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2013 | 604 | 0.350 |
Why?
|
| Learning Curve | 1 | 2011 | 208 | 0.350 |
Why?
|
| Middle Aged | 40 | 2021 | 213383 | 0.350 |
Why?
|
| Prosthesis Failure | 1 | 2014 | 1206 | 0.330 |
Why?
|
| Aged | 33 | 2021 | 163280 | 0.320 |
Why?
|
| Stents | 1 | 2020 | 3280 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 2 | 2023 | 7279 | 0.310 |
Why?
|
| Anastomosis, Surgical | 3 | 2018 | 987 | 0.290 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 1876 | 0.280 |
Why?
|
| Genital Neoplasms, Female | 2 | 2022 | 523 | 0.280 |
Why?
|
| Prostate | 4 | 2023 | 1774 | 0.270 |
Why?
|
| Androgen Antagonists | 3 | 2023 | 1377 | 0.270 |
Why?
|
| Urinary Bladder Diseases | 2 | 2008 | 166 | 0.270 |
Why?
|
| Iodine Radioisotopes | 1 | 2009 | 1032 | 0.270 |
Why?
|
| Video Recording | 1 | 2011 | 949 | 0.270 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2005 | 21 | 0.260 |
Why?
|
| Urinary Tract | 2 | 2019 | 309 | 0.260 |
Why?
|
| Retrospective Studies | 21 | 2022 | 77449 | 0.260 |
Why?
|
| Cholesterol | 3 | 2020 | 2917 | 0.250 |
Why?
|
| Salvage Therapy | 3 | 2021 | 1275 | 0.250 |
Why?
|
| Brachytherapy | 2 | 2010 | 1248 | 0.250 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2005 | 174 | 0.250 |
Why?
|
| Electrocoagulation | 2 | 2015 | 158 | 0.240 |
Why?
|
| Robotics | 1 | 2012 | 899 | 0.240 |
Why?
|
| Treatment Outcome | 19 | 2023 | 63114 | 0.240 |
Why?
|
| Physicians | 2 | 2012 | 4567 | 0.240 |
Why?
|
| Finasteride | 1 | 2004 | 90 | 0.230 |
Why?
|
| Endoscopy | 2 | 2012 | 1785 | 0.220 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2004 | 107 | 0.220 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 4931 | 0.220 |
Why?
|
| Vaginal Neoplasms | 1 | 2022 | 106 | 0.200 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2021 | 29 | 0.200 |
Why?
|
| Urinary Retention | 2 | 2017 | 111 | 0.200 |
Why?
|
| Laparoscopy | 5 | 2021 | 2151 | 0.200 |
Why?
|
| Constriction, Pathologic | 2 | 2018 | 1107 | 0.200 |
Why?
|
| Membrane Proteins | 1 | 2018 | 7880 | 0.200 |
Why?
|
| Hematuria | 1 | 2002 | 235 | 0.180 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 3396 | 0.180 |
Why?
|
| Carcinoma in Situ | 1 | 2006 | 806 | 0.180 |
Why?
|
| Intraoperative Period | 1 | 2020 | 520 | 0.170 |
Why?
|
| Cadaver | 2 | 2021 | 1337 | 0.170 |
Why?
|
| Sterols | 1 | 2018 | 63 | 0.160 |
Why?
|
| Urethral Diseases | 1 | 2018 | 53 | 0.160 |
Why?
|
| Color | 1 | 2019 | 307 | 0.160 |
Why?
|
| Time Factors | 7 | 2021 | 40075 | 0.150 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 2291 | 0.150 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 57776 | 0.150 |
Why?
|
| Societies, Medical | 2 | 2021 | 3743 | 0.150 |
Why?
|
| Mitochondrial Membranes | 1 | 2018 | 175 | 0.150 |
Why?
|
| Aerosols | 1 | 2020 | 625 | 0.150 |
Why?
|
| Prostheses and Implants | 1 | 2004 | 1387 | 0.150 |
Why?
|
| 3T3 Cells | 1 | 2018 | 1101 | 0.140 |
Why?
|
| United States | 10 | 2021 | 69872 | 0.140 |
Why?
|
| Incidence | 3 | 2021 | 20947 | 0.140 |
Why?
|
| Enzyme Inhibitors | 2 | 2005 | 3798 | 0.140 |
Why?
|
| Cricetulus | 1 | 2018 | 816 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2021 | 1842 | 0.140 |
Why?
|
| Logistic Models | 4 | 2012 | 13408 | 0.140 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2016 | 60 | 0.140 |
Why?
|
| Drainage | 1 | 2021 | 1142 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2021 | 35421 | 0.130 |
Why?
|
| CHO Cells | 1 | 2018 | 1406 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2011 | 4687 | 0.130 |
Why?
|
| Reoperation | 2 | 2018 | 4201 | 0.130 |
Why?
|
| Treatment Failure | 1 | 2021 | 2618 | 0.130 |
Why?
|
| Lumbosacral Plexus | 1 | 2015 | 53 | 0.130 |
Why?
|
| Amyloidosis | 1 | 2002 | 795 | 0.130 |
Why?
|
| Valsalva Maneuver | 1 | 2014 | 92 | 0.120 |
Why?
|
| Female | 18 | 2022 | 380194 | 0.120 |
Why?
|
| Hawaii | 1 | 2013 | 105 | 0.120 |
Why?
|
| Radiotherapy | 2 | 2014 | 1533 | 0.120 |
Why?
|
| Sequence Alignment | 1 | 2018 | 2256 | 0.120 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 665 | 0.120 |
Why?
|
| Biological Transport | 1 | 2018 | 2118 | 0.120 |
Why?
|
| Thermogenesis | 1 | 2017 | 435 | 0.110 |
Why?
|
| Exercise Therapy | 2 | 2011 | 906 | 0.110 |
Why?
|
| Ureteroscopes | 1 | 2013 | 23 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 6364 | 0.110 |
Why?
|
| Preoperative Care | 3 | 2018 | 2250 | 0.110 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2017 | 635 | 0.110 |
Why?
|
| Hepatocytes | 1 | 2020 | 1211 | 0.110 |
Why?
|
| Fibrosis | 3 | 2016 | 2029 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 7181 | 0.110 |
Why?
|
| Preoperative Period | 1 | 2015 | 549 | 0.110 |
Why?
|
| Prosthesis-Related Infections | 1 | 2018 | 538 | 0.110 |
Why?
|
| Endoplasmic Reticulum | 1 | 2018 | 1144 | 0.110 |
Why?
|
| Fecal Incontinence | 1 | 2015 | 239 | 0.110 |
Why?
|
| Interleukin-10 | 1 | 2017 | 1200 | 0.100 |
Why?
|
| Prognosis | 3 | 2018 | 29063 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2019 | 1180 | 0.100 |
Why?
|
| Lasers | 1 | 2015 | 952 | 0.100 |
Why?
|
| Consensus | 2 | 2017 | 2959 | 0.100 |
Why?
|
| Lasers, Solid-State | 1 | 2013 | 169 | 0.100 |
Why?
|
| Adult | 11 | 2021 | 214055 | 0.090 |
Why?
|
| Age Factors | 3 | 2012 | 18370 | 0.090 |
Why?
|
| Adipocytes | 1 | 2017 | 1184 | 0.090 |
Why?
|
| Urinary Incontinence, Urge | 1 | 2011 | 46 | 0.090 |
Why?
|
| Electrodes, Implanted | 1 | 2015 | 824 | 0.090 |
Why?
|
| Muscarinic Antagonists | 1 | 2011 | 137 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2005 | 4599 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 8642 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 2915 | 0.090 |
Why?
|
| Biofeedback, Psychology | 1 | 2010 | 115 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 2916 | 0.090 |
Why?
|
| Cell Membrane | 1 | 2018 | 3748 | 0.080 |
Why?
|
| Obesity | 1 | 2011 | 12745 | 0.080 |
Why?
|
| Organ Size | 4 | 2018 | 2252 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 4 | 2020 | 21827 | 0.080 |
Why?
|
| Cancer Care Facilities | 1 | 2010 | 402 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 9239 | 0.080 |
Why?
|
| Risk Factors | 6 | 2021 | 72290 | 0.080 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 1889 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2012 | 1654 | 0.080 |
Why?
|
| Cell Line | 2 | 2018 | 15997 | 0.070 |
Why?
|
| Physical Therapy Modalities | 1 | 2011 | 550 | 0.070 |
Why?
|
| Prospective Studies | 5 | 2021 | 53288 | 0.070 |
Why?
|
| Internationality | 1 | 2012 | 1003 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2017 | 2899 | 0.070 |
Why?
|
| Homeostasis | 1 | 2016 | 3340 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2018 | 5021 | 0.060 |
Why?
|
| SEER Program | 1 | 2010 | 1508 | 0.060 |
Why?
|
| Palliative Care | 1 | 2020 | 3493 | 0.060 |
Why?
|
| Quality of Life | 3 | 2021 | 12804 | 0.060 |
Why?
|
| Hypertension, Renovascular | 1 | 2005 | 123 | 0.060 |
Why?
|
| Azasteroids | 1 | 2004 | 38 | 0.060 |
Why?
|
| Hematocrit | 1 | 2005 | 636 | 0.060 |
Why?
|
| Kidney Pelvis | 1 | 2005 | 188 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 3508 | 0.060 |
Why?
|
| Disease Management | 1 | 2014 | 2459 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 39050 | 0.050 |
Why?
|
| Titanium | 1 | 2004 | 494 | 0.050 |
Why?
|
| Pubic Bone | 1 | 2021 | 29 | 0.050 |
Why?
|
| Serum Amyloid A Protein | 1 | 2002 | 121 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 9959 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2022 | 10252 | 0.050 |
Why?
|
| Phosphates | 1 | 2004 | 786 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 1061 | 0.050 |
Why?
|
| Instillation, Drug | 1 | 2020 | 32 | 0.050 |
Why?
|
| Comorbidity | 2 | 2012 | 10388 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2010 | 5078 | 0.050 |
Why?
|
| Animals | 6 | 2020 | 168757 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2017 | 9146 | 0.040 |
Why?
|
| Mice | 4 | 2020 | 81183 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2014 | 5102 | 0.040 |
Why?
|
| General Surgery | 1 | 2010 | 1636 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2005 | 1050 | 0.040 |
Why?
|
| Activating Transcription Factors | 1 | 2017 | 29 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2018 | 40561 | 0.040 |
Why?
|
| Supine Position | 1 | 2018 | 205 | 0.040 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2017 | 103 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2019 | 539 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2015 | 12720 | 0.040 |
Why?
|
| Medicare | 1 | 2015 | 6566 | 0.040 |
Why?
|
| Prevalence | 1 | 2013 | 15226 | 0.040 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group C | 1 | 2016 | 14 | 0.040 |
Why?
|
| Sterol Regulatory Element Binding Proteins | 1 | 2016 | 27 | 0.040 |
Why?
|
| Pressure | 1 | 2020 | 1203 | 0.040 |
Why?
|
| Hyperthermia, Induced | 1 | 2020 | 403 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 15076 | 0.030 |
Why?
|
| Survival Rate | 1 | 2010 | 12788 | 0.030 |
Why?
|
| Patient Positioning | 1 | 2018 | 324 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2021 | 1915 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 2020 | 1150 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 11031 | 0.030 |
Why?
|
| Random Allocation | 1 | 2019 | 2429 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 6489 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2015 | 23338 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2005 | 3461 | 0.030 |
Why?
|
| Cisplatin | 1 | 2020 | 1662 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2020 | 2234 | 0.030 |
Why?
|
| Disease Progression | 1 | 2010 | 13284 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2020 | 19229 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 12245 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 969 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2015 | 934 | 0.020 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2015 | 454 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 1641 | 0.020 |
Why?
|
| Patient Selection | 1 | 2021 | 4215 | 0.020 |
Why?
|
| Ligands | 1 | 2016 | 3282 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2016 | 2017 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 15540 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2020 | 9734 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 3616 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2018 | 5985 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6538 | 0.020 |
Why?
|
| Self Report | 1 | 2015 | 3558 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2017 | 23403 | 0.010 |
Why?
|
| Rectum | 1 | 2008 | 904 | 0.010 |
Why?
|
| Renin | 1 | 2005 | 642 | 0.010 |
Why?
|
| Testicular Neoplasms | 1 | 2009 | 804 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 5391 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2008 | 1486 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 12354 | 0.010 |
Why?
|
| Liver | 1 | 2016 | 7474 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 19905 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 2009 | 1206 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 13989 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11524 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 12072 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2010 | 8324 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 2541 | 0.010 |
Why?
|
| Algorithms | 1 | 2017 | 13881 | 0.010 |
Why?
|